Phase II Trial Evaluating the Safety and Efficacy of Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 22 Mar 2016 Status changed from active, no longer recruiting to completed.
- 23 Feb 2016 Planned End Date changed from 1 Jan 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
- 08 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.